zkajbfWvFFrTiUUOWbK
名前：Wilford日付：2015/01/04 22:34:15
A financial advisor glucovance online no prescription Goldman Sachs analysts noted that the potential entrant presents more of a problem for Lantus, which is slated to go off-patent in 2015, than to Levemir. While lack of Interchangeability could limit the biosimilar somewhat, the analysts forecast Lilly's glargine to gain a 6% share of sales in the basal market by 2020 and to be priced at a 15%-20% discount to Lantus.Â
ログイン
